Exai Bio

Developer of RNA biomarkers and AI platform for cancer detection

placePalo Alto, California, United States calendar_todayFounded 2018 groups47 employees language exai.bio

Innovation

5 patent families — focus: Physics & computing, Chemistry & metallurgy, Human necessities; filing pace active. Cited 20 times.

YearFilings
20241
20254
20262

Social engagement

Social engagement: 6.3K social following, 10 posts in the last 12 months — below the industry typical range.

Investor mix

5 investors on record; lead investors include Casdin Capital, S32.

Investor typeCountShare
Venture capital480%
Other / undisclosed120%

Hiring activity

Hires occasionally

1 role tracked across 1 of the last 12 months

Based on job postings tracked across public sources.

Recent activity

7 May 2026
Partnership
Deviation Capital
27 Apr 2026
Product launch
Medscape feature
2 Feb 2026
Product launch
Exai generative AI models for liquid biopsy tests
Coming soon